Literature DB >> 2902043

Immunosuppressive activity of human amniotic fluid of normal and abnormal pregnancies.

B Shohat1, J M Faktor.   

Abstract

Twenty specimens of amniotic fluid (AF) obtained between week 16 and 18 of gestation from normal pregnant women and six specimens from pregnant women in which trisomia of chromosome 21 was found were tested for immunosuppressive activity. Incubation of normal human donor lymphocytes with 0.2-1 mL of AF from normal pregnant women for one hour at 37 degrees C was sufficient for induction of significant inhibition of the ability of these cells to induce a local xenogeneic graft-versus-host reaction (GVHR) as well as inhibition of E and E-active rosette formation, the GVHR being the most sensitive test. On the other hand, amniotic fluid obtained from the six pregnant women in which trisomia of chromosome 21 was found showed no inhibitory activity in either the E or E-active rosette formation, nor in the local xenogeneic graft-versus-host reaction. AF from all the women tested was found to have no effect on phenotype expression of the lymphocytes, as tested by the monoclonal antibodies OKT4+ and OKT8+, nor on B-lymphocytes, as tested by surface immunoglobulins. No correlation was found between the alpha-fetoprotein levels in the sera of those women and the immunosuppressive activity. These findings indicate that genetic defects of the conceptus are not limited to the embryo but may affect the composition of immunosuppressive components present in normal amniotic fluid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902043

Source DB:  PubMed          Journal:  Int J Fertil        ISSN: 0020-725X


  2 in total

Review 1.  Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates.

Authors:  Ravid Shechter; Anat London; Michal Schwartz
Journal:  Nat Rev Immunol       Date:  2013-03       Impact factor: 53.106

2.  The immunomodulatory activity of human amniotic fluid can be correlated with transforming growth factor-beta 1 (TGF-beta 1) and beta 2 activity.

Authors:  A K Lang; R F Searle
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.